2024 - in progress
|
- Technical and Administrative Staff (PTA) –D1. Work activity carried out at the Department of Translational Medicine, University of Ferrara
|
2019-2024
|
- Researcher (RTD-A). 06/D3-Blood diseases, oncology and rheumatology - MED/06-Medical Oncology. Work activity carried out at the Department of Morphology, Surgery and Experimental Medicine/Department of Translational Medicine, University of Ferrara
|
2018-2019
|
- Continuous and exclusively personal collaboration contract Art.2222 c.c, stipulated at the Consorzio Futuro in Ricerca.
|
2016-2018
|
- Research fellow (Assegnista di ricerca), Department of Morphology, Surgery and Experimental Medicine, University of Ferrara - MED/06.
|
2011-2016
|
- Research fellow (Assegnista di ricerca), Department of Morphology, Surgery and Experimental Medicine, University of Ferrara - MED/06.
|
2008-2010
|
- Three-year fellow-ship “Marino Fontana and Maria Lionello”, Italian Foundation for Cancer Research (FIRC), carried out at the Department of Experimental and Diagnostic Medicine, Microbiology Section, University of Ferrara.
|
2006-2008
|
- Ohio State University Research Scholar fellowship: Department of Molecular Virology, Immunology and Medical Genetics, Prof. Carlo Maria Croce’s Laboratory, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio (USA)
|
2004-2006
|
- PhD in Biochemistry, Molecular Biology and Biotechnology, at the University of Ferrara, Department of Experimental and Diagnostic Medicine
|
2002-2003
|
- Research training grant under the community research contract QLG2-CT-1999-00786, carried out at the Department of Experimental and Diagnostic Medicine, of Ferrara.
|
RESEARCH AREA
|
- Dr. Callegari's scientific activity has mainly focused on the study of hepatocellular carcinoma (HCC), also through the development and use of mouse models to study the role of genes and microRNAs (miRNAs) in the etiopathogenesis of the disease. She has also focused her studies on the effects of drugs and miRNAs in the treatment of HCC, in order to improve the therapeutic efficacy of drugs already used in clinical use in humans, overcome drug resistance and test new molecules with therapeutic activity. Dr. Callegari's is co-author of 34 publications in international peer-reviewed scientific journals (December 2024) (H-index: 23). Author code: ORCID: 0000-0002-4969-5400; Scopus Author ID: 8603707900
|
|